On November 18, 2026 Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor, reported that the United States Patent and Trademark Office ("USPTO") has granted a U.S. patent covering stenoparib treatment regimens. The patent is to provide protection for the claimed methods into 2045.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity’s clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.
"The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval".
The patent complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. Together, these patents enable the Company’s strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.
The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.
(Press release, Allarity Therapeutics, NOV 18, 2026, View Source [SID1234674920])